Tarsus Pharmaceuticals, Inc. Detailed Financials

Full historical quarterly statements

Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-30
Total Revenue162.1M151.7M118.7M102.7M78.3M66.4M48.1M40.8M
Cost of Goods Sold9.4M10.9M24.6M6.2M5.2M4.9M3.2M3.0M
Gross Profit152.7M140.7M94.1M96.4M73.1M61.5M44.9M37.8M
R&D Expenses22.4M18.0M16.3M15.6M14.4M16.9M12.1M12.3M
Operating Expenses158.8M148.7M108.6M118.6M99.4M85.9M70.0M71.1M
Operating Income-6.1M-8.0M-14.5M-22.2M-26.3M-24.4M-25.2M-33.3M
Other Income / Gains-3.2M1.7M1.9M1.8M1.2M1.3M1.7M12K
Net Income-7.0M-8.4M-12.6M-20.3M-25.1M-23.1M-23.4M-33.3M
EPS (Diluted)-0.16-0.20-0.30-0.48-0.64-0.60-0.61-0.88
Reported CurrencyUSDUSDUSDUSDUSDUSDUSDUSD
Gross Profit Ratio0.9420.9280.7930.9390.9330.9260.9330.926
General And Administrative Expenses00000000
Selling And Marketing Expenses00000000
Selling General And Administrative Expenses136.4M130.7M108.6M103.0M85.0M69.0M57.9M58.8M
Other Expenses00-16.3M00000
Cost And Expenses168.2M159.6M133.2M124.8M104.6M90.8M73.3M74.1M
Interest Income3.7M4.0M1.8M4.2M3.5M3.6M4.1M4.1M
Interest Expense2.1M2.2M02.1M2.1M2.2M2.3M2.1M
Depreciation And Amortization437K443K460K453K460K432K300K239K
Ebitda-5.7M-3.7M-12.1M-17.6M-22.4M-20.4M-20.7M-30.9M
Ebitdaratio-0.035-0.024-0.102-0.172-0.287-0.307-0.43-0.758
Operating Income Ratio-0.038-0.053-0.122-0.216-0.335-0.368-0.523-0.816
Income Before Tax-9.3M-6.3M-12.6M-20.3M-25.1M-23.1M-23.4M-33.3M
Income Before Tax Ratio-0.058-0.042-0.106-0.198-0.321-0.348-0.487-0.816
Income Tax Expense-2.4M2.1M000000
Net Income Ratio-0.043-0.055-0.106-0.198-0.321-0.348-0.487-0.816
Epsdiluted-0.16-0.20-0.30-0.48-0.64-0.60-0.61-0.88
Weighted Average Shs Out43.0M42.8M42.6M42.4M39.3M38.6M38.4M37.8M
Weighted Average Shs Out Dil43.0M42.8M42.6M42.4M39.3M38.6M38.4M37.8M